Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Twenty one of 32 AD patients still on A2-73 sounds encouraging but it's a very small sample size and we know little about the individual patients. AD patients do not all decline uniformly or at a steady rate and can be stable for considerable periods of time with or without medication or other interventions before they suddenly decline. As I said, 21 out of 32 still on the drug sounds encouraging and maybe it's significant, but not necessarily. We really won't know until much larger trials are completed. I am cautiously optimistic based on the very early data but we all know that often times drugs that look great in small Phase 2 trials fail in larger Phase 3 trials. Therefore, ultimate outcome is still TBD.